This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
11 Apr 2016

Rentschler: 4th Laupheim Biotech Days to take place 13–14 June 2016

Exciting lectures and discussions on therapeutic fusion proteins.

The Laupheim Biotech Days — formerly known as Laupheimer Zelltage — provide a unique platform for the international exchange of knowledge, ideas and expertise. A comprehensive overview is given and experts discuss cutting-edge technologies and techniques. The 4th Laupheim Biotech Days will take place June 13 to 14, 2016. The event is organized by Rentschler, a leading contract development and manufacturing organization focused on biopharmaceuticals.

This conference with the title "Fusion Proteins - delivering novel therapeutic options" is focused on the state of the art in developing fusion proteins as biopharmaceuticals, shedding light on the immense potential of design and functionality.

Fusion proteins belong to the most lucrative biotech drugs. The highly diverse pipeline is constantly growing with more than 80 molecules in clinical trials and five newly approved molecules in 2014 alone. This dynamic growth is primarily driven by three trends: Establishing platform technologies to extend plasma half-life, innovative approaches addressing multiple targets simultaneously and novel toxic constructs with superior selectivity. Therefore, it is worthwhile to dedicate a closer look to this exciting class of therapeutics.

A highlight of the event are the presentations by international speakers. Topics are among others toxic constructs, antibody derived molecules and bispecific scaffolds. At the first conference day, you will have the opportunity to participate at a tour of Rentschler’s facility. There will be also an industrial exhibition with companies showing their innovations and services. The deadline to register is 13 May 2016.

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.